Lantheus Holdings Inc. is making waves in M&A with its second big deal of the month – and year – the acquisition of Evergreen Theragnostics Inc. for $250 million in cash up front and up to an additional $752.5 million in contingent payments. The transaction follows announcement of a definitive agreement to acquire Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., on Jan. 13 for $350 million in cash at closing and a further $400 million in milestone payments.

Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.

Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.